User contributions for Alara E. Dagsali

Results for Alara E. Dagsali talk block log uploads logs
A user with 163 edits. Account created on 21 August 2023.
Jump to navigation Jump to search
Search for contributionsExpandCollapse
⧼contribs-top⧽
⧼contribs-date⧽
(newest | oldest) View (newer 50 | ) (20 | 50 | 100 | 250 | 500)

30 April 2025

  • 19:1019:10, 30 April 2025 diff hist +49,230 N Oliceridine Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=oliceridine |aOrAn=an |drugClass=μ opioid agonist |indication=OLINVYK is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. |hasBlackBoxWarning=Yes |adverseReactions=The following adverse reactions are described, or described in greater detail, in other sections: *Addi..." current
  • 18:3818:38, 30 April 2025 diff hist +16,108 N Viltolarsen Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=viltolarsen |aOrAn=a |drugClass=exon 53 of the dystrophin pre-mRNA |indicationType=treatment |indication=Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated..." current
  • 18:2218:22, 30 April 2025 diff hist +21,434 N Satralizumab-mwge Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=satralizumab-mwge |aOrAn=a |drugClass=interleukin inhibitors |indication=ENSPRYNG is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. |adverseReactions=The following clinically significant adverse reactions are described elsewhere in the labeling: *Infections *Elevated Liver Enzym..." current
  • 09:5509:55, 30 April 2025 diff hist −24 Clascoterone No edit summary current
  • 09:5409:54, 30 April 2025 diff hist +13,347 N Clascoterone Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=Clascoterone |aOrAn=a |drugClass=androgen receptor antagonist |indicationType=treatment |indication=WINLEVI (clascoterone) cream is an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Conditi..."
  • 08:5308:53, 30 April 2025 diff hist +32,450 N Somapacitan-beco Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=somapacitan-beco |aOrAn=a |drugClass=binds to the growth hormone receptor and induces intracellular signalling to up-regulate insulin-like growth factor I (IGF-1) |indicationType=treatment |indication=SOGROYA is indicated for the: *Treatment of pediatric patients aged 2.5 years and older who have growth failure due to inadequate secretion of endogenous growth hormone (GH). *Repla..." current
  • 05:5605:56, 30 April 2025 diff hist +16,238 N Copper cu 64 dotatate injection Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=copper cu 64 dotatate injection |aOrAn=a |drugClass=somatostatin receptor-positive neuroendocrine tumors (NETs) |indicationType=diagnosis |indication=Detectnet is indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients. |adverseReactions=The following clinically significant adverse r..." current

29 April 2025

  • 21:1321:13, 29 April 2025 diff hist +24,649 N Pralsetinib Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=pralsetinib |aOrAn=a |drugClass=RET receptor tyrosine kinase inhibitor |indicationType=treatment |indication=of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. |adverseReactions=*Interstitial Lung Disease/Pneumonitis *Hypertension *Hepatotoxicity *Hemorrhagic Events *Tumor Lysis Syndrome *Risk of Im..." current
  • 20:5420:54, 29 April 2025 diff hist +13,818 N Atoltivimab, maftivimab, and odesivimab-ebgn Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=atoltivimab, maftivimab, and odesivimab-ebgn |aOrAn=a |drugClass=fixed-dose combination of three monoclonal antibodies |indicationType=treatment |indication=of infection caused by Orthoebolavirus zairense in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Orthoebolavirus zairense infection |adverseReactions=Hypersensitivity Reactions Inc..." current
  • 20:4220:42, 29 April 2025 diff hist +22,253 N Lonafarnib b Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=lonafarnib |aOrAn=a |drugClass=direct farnesyl transferase inhibitor |indication=ZOKINVY is indicated in patients 12 months of age and older with a body surface area (BSA) of 0.39 m2 and above: *To reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS) *For the treatment of processing-deficient Progeroid Laminopathies with either: - Heterozygous LMNA mut..." current
  • 19:5919:59, 29 April 2025 diff hist +14,552 N Lumasiran Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=lumsiran |aOrAn=an |drugClass=inhibits oxalate synthesis |indicationType=treatment |indication=of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in pediatric and adult patients |adverseReactions=*Injection site reaction *Abdominal pain* |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#..." current
  • 19:4519:45, 29 April 2025 diff hist +23,681 N Setmelanotide Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=setmelanotide |aOrAn=a |drugClass=melanocortin-4 receptor (MC4R) agonist |indication=IMCIVREE is indicated for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to: |adverseReactions=*'''Disturbance in Sexual Arousal''' *'''Depression and Suicidal Ideation''' *'''Hypersensitivity Reactions''' *'''Skin Pigme..." current

27 April 2025

  • 18:0218:02, 27 April 2025 diff hist +5 Naxitamab No edit summary current
  • 18:0118:01, 27 April 2025 diff hist +25,571 N Naxitamab Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=naxitamab |aOrAn=a |drugClass=IgG1 monoclonal antibody directed against GD2 disialogangliosides |indicationType=treatment |indication=of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy. |hasBlackBox..."
  • 17:2517:25, 27 April 2025 diff hist +23,551 N Berotralstat Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=berotralstat |aOrAn=a |drugClass=plasma kallikrein inhibitor |indicationType=prophylaxis |indication=to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older. |adverseReactions=QT Prolongation |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</..." current
  • 17:0517:05, 27 April 2025 diff hist +15,403 N Tirbanibulin Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=tirbanibulin |aOrAn=a |drugClass=non-ATP competitive Src kinase inhibitor and tubulin polymerization inhibitor. |indicationType=treatment |indication=of actinic keratosis on the face or scalp |adverseReactions=*Application site pruritus *Application site paina |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">..." current
  • 16:1416:14, 27 April 2025 diff hist +21,662 N Margetuximab Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=margetuximab |aOrAn=a |drugClass=HER2/neu receptor antagonist |indicationType=treatment |indication=of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease |hasBlackBoxWarning=Yes |adverseReactions='''Left Ventricular Dysfunction''' '''Embryo-Fetal Toxicity''' '''Infusio..." current
  • 15:5415:54, 27 April 2025 diff hist +24,276 N Relugolix Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=relugolix |aOrAn=a |drugClass=gonadotropin-releasing hormone (GnRH) receptor antagonist |indicationType=treatment |indication=of adult patients with advanced prostate cancer. |adverseReactions=QT/QTc Interval Prolongation |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |fdaL..." current
  • 14:5614:56, 27 April 2025 diff hist +18,021 N Ansuvimab-zykl Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=Ebanga |aOrAn=a |drugClass=ebolavirus (EBOV) glycoprotein 1 (GP1)-directed recombinant, human Immunoglobulin G1 (IgG1) monoclonal antibody. |indicationType=treatment |indication=of infection caused by Orthoebolavirus zairense(formerly Zaire ebolavirus) in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Orthoebolavirus zairense infection..." current
  • 14:2114:21, 27 April 2025 diff hist +20,784 N Vibegron Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=Gemtesa |aOrAn=a |drugClass=selective beta-3 adrenergic receptor |indicationType=treatment |indication=of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults. treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adult males on pharmacological therapy for benig..." current

10 April 2025

  • 11:5311:53, 10 April 2025 diff hist +14,877 N Givinostat Hydrochloride Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=givinostat |aOrAn=an |drugClass=inhibits class I and class II histone deacetylases (HDACs) and several pro-inflammatory cytokines |indicationType=treatment |indication=of Duchenne muscular dystrophy (DMD) in patients 6 years of age and older. |adverseReactions=*Hematological Changes *Increased Triglycerides *Gastrointestinal Disturbances *QTc Prolongation |blackBoxWarningTitle='..." current
  • 10:3310:33, 10 April 2025 diff hist +18,496 N Sotatercept-csrk Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName= Alara Ece Dagsali, M.D. |aOrAn=an |drugClass=activin signalling inhibitor |indicationType=treatment |indication=of adults with pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) to increase exercise capacity, improve WHO functional class (FC), and reduce the risk of clinical worsening events. |adverseReactions=*Erythrocytosis *Severe Thr..." current
  • 06:0306:03, 10 April 2025 diff hist +16,208 N Nogapendekin alfa inbakicept-pmln Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=nogapendekin alfa inbakicept-pmln |aOrAn=an |drugClass=interleukin-15 (IL-15) receptor agonist |indicationType=treatment |indication=of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. |adverseReactions=The most common (≥15%) adverse reactions, were increased creatinine, dysuria, hematuri..." current

20 March 2025

18 March 2025

  • 20:5820:58, 18 March 2025 diff hist +29,524 N Danicopan Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=Danicopan |aOrAn=a |drugClass=medication |indicationType=treatment |indication=VOYDEYA is indicated as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH). |hasBlackBoxWarning=Yes |adverseReactions=*Serious Infections Caused by Encapsulated Bacteria *Hepatic Enzyme Increase *Hyperl..." current
  • 20:3920:39, 18 March 2025 diff hist +69 Alara E. Dagsali No edit summary current Tag: Visual edit: Switched
  • 20:3620:36, 18 March 2025 diff hist +36,115 N Ceftobiprole medocaril sodium Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=ceftobiprole medocaril sodium |aOrAn=a |drugClass=beta-lactam class of antibiotics |indicationType=treatment |indication='''1.1 Staphylococcus aureus Bloodstream Infection (Bacteremia)''' ZEVTERA is indicated for the treatment of adult patients with Staphylococcus aureus bloodstream infection (bacteremia) (SAB), including those with right-sided infective endocarditis, caused by me..." current
  • 19:5019:50, 18 March 2025 diff hist +96 Pegulicianine No edit summary current
  • 19:4819:48, 18 March 2025 diff hist +17,199 N Pegulicianine Created page with "{{DrugProjectFormSinglePage |authorTag=User:AED |genericName=pegulicianine |aOrAn=a |drugClass=diagnostic imaging agent |indicationType=diagnosis |indication=LUMISIGHT is indicated for fluorescence imaging in adults with breast cancer as an adjunct for the intraoperative detection of cancerous tissue within the resection cavity following removal of the primary specimen during lumpectomy surgery. |hasBlackBoxWarning=Yes |adverseReactions=*Anaphylaxis and Other Serious Hyp..."

6 March 2025

4 March 2025

17 December 2024

16 May 2024

  • 07:0707:07, 16 May 2024 diff hist +21 User:AED No edit summary current
  • 07:0607:06, 16 May 2024 diff hist +3 Diclofenac Patch No edit summary current
  • 07:0607:06, 16 May 2024 diff hist +48,610 N Diclofenac Patch Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |OTC=Yes |genericName=DICLOVIX |indicationType=treatment |indication=Diclofenac sodium topical solution is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s). |hasBlackBoxWarning=Yes |adverseReactions=Dry Skin (Application Site) Contact Dermatitis (Application Site) Dyspepsia Abdominal Pain Flatulence Pruritus (Application Site) Diarr..."
  • 06:4206:42, 16 May 2024 diff hist +24 User:AED No edit summary
(newest | oldest) View (newer 50 | ) (20 | 50 | 100 | 250 | 500)
Retrieved from "https://www.wikidoc.org/index.php/Special:Contributions/Alara_E._Dagsali"